Aztreonam + avibactam injection is an intravenous antibacterial combination used in specific clinical settings involving susceptible Gram-negative bacteria. Along with understanding its mechanism, dosing, susceptibility and clinical evidence, healthcare professionals need to understand its safety profile, adverse reactions, contraindications, warnings and monitoring considerations.
Safety information for aztreonam + avibactam comes from clinical studies, regulatory evaluation and approved product information. Because safety warnings and preparation requirements can be product-specific, healthcare professionals should always consult the current prescribing information applicable to the product being administered.
This article provides an overview of important safety considerations associated with aztreonam + avibactam injection, with an emphasis on adverse reactions, hypersensitivity, hepatic and renal considerations, monitoring and clinically relevant precautions.
What Is Known About the Safety of Aztreonam + Avibactam Injection?
The safety profile of aztreonam + avibactam has been evaluated through clinical development programs and regulatory review.
The most important safety considerations include:
- hypersensitivity reactions;
- gastrointestinal adverse reactions;
- hepatic laboratory abnormalities;
- hematologic abnormalities;
- electrolyte abnormalities;
- serious skin reactions;
- Clostridioides difficile-associated diarrhea;
- renal-function considerations; and
- potential drug-interaction considerations.
The frequency and severity of individual adverse reactions can vary depending on the patient population, underlying illness, concomitant medicines and the specific product information being referenced.
For this reason, adverse reactions should be interpreted in the context of the applicable approved prescribing information rather than considered in isolation.
What Are the Common Adverse Reactions of Aztreonam + Avibactam?
Clinical and regulatory sources identify several adverse reactions that healthcare professionals should be aware of during treatment.
The current UK product information identifies anaemia, diarrhea, increased alanine aminotransferase (ALT) and increased aspartate aminotransferase (AST) among commonly reported adverse drug reactions. 3
U.S. product information also identifies adverse reactions including:
- hepatic laboratory abnormalities;
- anemia;
- diarrhea;
- hypokalemia; and
- pyrexia.
The clinical importance of an individual laboratory abnormality depends on its degree, duration, associated symptoms and the patient’s underlying condition.
Hematologic Reactions
Changes in blood-cell parameters, including anemia, have been reported during treatment.
Where clinically appropriate, healthcare professionals may consider the patient’s baseline hematologic status and relevant laboratory findings when evaluating new symptoms or abnormalities during therapy.
Gastrointestinal Reactions
Diarrhea is among the reported adverse reactions associated with aztreonam + avibactam.
Persistent or severe diarrhea during or after antibacterial treatment requires appropriate clinical assessment because antibiotic exposure can be associated with Clostridioides difficile-associated diarrhea.
Hepatic Laboratory Abnormalities
Increases in liver enzymes such as ALT and AST have been reported.
An isolated increase in a liver enzyme does not necessarily indicate clinically significant liver injury. Results should be interpreted alongside the patient’s symptoms, medical history and other laboratory findings.
What Serious Safety Risks Should Healthcare Professionals Recognize?
Some adverse reactions require particular attention because they may become clinically significant or require urgent intervention.
Hypersensitivity Reactions
As with other beta-lactam antibacterial agents, hypersensitivity reactions are an important safety consideration.
Healthcare professionals should be alert for clinical signs such as:
- rash;
- urticaria;
- bronchospasm;
- facial or airway swelling;
- hypotension; and
- anaphylaxis.
Patients with a history of serious hypersensitivity reactions to beta-lactam antibiotics require particular attention when treatment is being considered.
If a serious hypersensitivity reaction occurs, appropriate clinical management should be initiated according to established medical protocols.
Serious Skin Reactions
Serious skin disorders are included among the safety warnings associated with the product information for aztreonam + avibactam.
Healthcare professionals should evaluate significant or rapidly progressing skin reactions, particularly when accompanied by systemic symptoms.
The specific diagnosis and management should be based on the patient’s clinical presentation and applicable prescribing information.
Clostridioides difficile-Associated Diarrhea
Antibacterial treatment can be associated with C. difficile-associated diarrhea.
Healthcare professionals should consider this possibility when a patient develops significant or persistent diarrhea during or following antibacterial therapy.
Clinical evaluation is particularly important when diarrhea is severe, persistent or associated with other concerning symptoms.
Hepatic Adverse Reactions
Hepatic laboratory abnormalities have been reported with aztreonam + avibactam.
The U.S. prescribing information recommends monitoring liver-related laboratory tests when clinically appropriate. 3
Monitoring should be interpreted in the context of:
- baseline hepatic function;
- existing liver disease;
- concomitant medicines;
- changes in ALT or AST;
- bilirubin and other relevant laboratory findings; and
- clinical symptoms suggestive of hepatic dysfunction.
What Are the Contraindications and Key Precautions?
Hypersensitivity to Aztreonam or Avibactam
Known serious hypersensitivity to the active components is an important contraindication or precaution depending on the applicable product labeling.
Before treatment, healthcare professionals should review the patient’s documented allergy history.
Severe Beta-Lactam Hypersensitivity
A history of severe hypersensitivity to beta-lactam antibiotics requires careful consideration.
The clinical history should be reviewed rather than relying only on the broad description of “penicillin allergy” or “beta-lactam allergy.”
The severity and nature of the previous reaction are important when assessing risk.
Renal Impairment
Renal function is an important consideration during aztreonam + avibactam therapy because renal impairment can affect drug exposure and dosing requirements.
This article does not replace the dedicated renal-dosing guidance.
Healthcare professionals should assess renal function according to the applicable prescribing information and adjust therapy where required.
For detailed dose adjustment information, refer to the dedicated aztreonam-avibactam renal dosing resource.
Hepatic Impairment
Hepatic status may also be relevant when evaluating the safety of treatment.
The European product information specifically addresses hepatic considerations and monitoring. 3
The focus should be on appropriate clinical and laboratory monitoring rather than assuming that hepatic abnormalities automatically require a particular dose adjustment.
What Monitoring May Be Relevant During Treatment?
Monitoring should be individualized according to the patient’s clinical condition, underlying diseases, concomitant medications and applicable product information.
Renal Function
Renal function is particularly important because renal impairment can affect exposure to aztreonam and avibactam.
Healthcare professionals may monitor relevant measures of renal function and reassess treatment when renal function changes significantly.
This is especially important in hospitalized patients whose renal function can change during an acute illness.
Liver-Related Laboratory Tests
Liver-related laboratory tests may be appropriate when clinically indicated.
Healthcare professionals should pay attention to:
- ALT;
- AST;
- bilirubin;
- other relevant hepatic laboratory findings; and
- symptoms suggesting liver dysfunction.
Clinical Signs of Hypersensitivity
Patients should be monitored for signs of an allergic or hypersensitivity reaction, particularly during administration and early treatment.
Symptoms such as rash, bronchospasm, swelling or hemodynamic instability require appropriate clinical assessment.
Gastrointestinal Symptoms
Persistent or significant diarrhea should not automatically be considered an uncomplicated antibiotic side effect.
Healthcare professionals should consider C. difficile-associated diarrhea when clinically appropriate.
Hematologic Considerations
Where clinically indicated, relevant blood parameters may be assessed, particularly in patients with pre-existing hematologic abnormalities or prolonged treatment.
Are There Important Drug-Interaction Considerations?
Drug-interaction assessment is an important part of safe antimicrobial therapy.
The FDA multidisciplinary review considered potential CYP- and transporter-mediated interactions involving aztreonam and avibactam. The review found no CYP-based interaction potential for the combination while also discussing OAT1/OAT3 considerations. 3
Healthcare professionals should still review the patient’s complete medication list before treatment, particularly when renal function is impaired or when medicines affecting renal transport are being considered.
Drug-interaction information should always be checked against current product-specific prescribing information.
What About Pregnancy and Breastfeeding?
Pregnancy and breastfeeding require an individual clinical assessment.
European product information indicates that aztreonam/avibactam should be used during pregnancy when clearly indicated, while available human information concerning avibactam during breastfeeding remains limited. 3
Healthcare professionals should therefore consider:
- the clinical need for treatment;
- available safety information;
- the patient’s pregnancy status;
- breastfeeding status; and
- available alternative treatment options.
The decision should be based on current local prescribing information and clinical judgment.
What Do Clinical Studies Tell Us About Safety?
Clinical trials provide an additional source of safety information alongside regulatory product labeling.
The REVISIT and ASSEMBLE studies provide clinical safety data from different patient populations.
The ASSEMBLE study, for example, evaluated aztreonam-avibactam in patients with infections caused by metallo-beta-lactamase-producing Gram-negative organisms. Because the study population was relatively small, its safety findings should be interpreted within the limitations of the study design and population. 3
Clinical studies are useful for understanding:
- adverse-event patterns;
- treatment-emergent adverse events;
- treatment-related events;
- discontinuations;
- serious adverse events; and
- safety observations in specific patient populations.
However, clinical-trial results should be interpreted together with the current regulatory safety information rather than used as a substitute for product labeling.
How Should Healthcare Professionals Interpret Aztreonam + Avibactam Safety Information?
A useful safety assessment considers more than simply counting adverse reactions.
Healthcare professionals should consider:
Patient Population
Clinical-trial populations may differ from the individual patient being treated.
A hospitalized patient with severe infection, renal dysfunction or multiple comorbidities may have a different risk profile from a clinical-trial participant.
Product Information
Current local prescribing information remains an important reference for:
- contraindications;
- warnings;
- adverse reactions;
- special populations;
- interactions; and
- monitoring.
Patient-Specific Risk Factors
Risk assessment should take into account:
- allergy history;
- renal function;
- hepatic status;
- concomitant medicines;
- previous antibiotic-associated diarrhea; and
- other relevant medical conditions.
Common Versus Serious Reactions
A commonly reported adverse reaction is not necessarily clinically more important than a rare but serious reaction.
Healthcare professionals should distinguish between:
Common adverse reactions
and
Potentially serious reactions requiring prompt clinical attention.
Meblanios and Aztreonam + Avibactam Injection
Meblanios is an AIONIOS Pharma product associated with the aztreonam + avibactam injectable combination.
Because safety information can be product-specific, healthcare professionals should distinguish general information about the aztreonam + avibactam combination from the specific prescribing, quality and safety information applicable to Meblanios.
For product-specific information, refer to the dedicated Meblanios Aztreonam + Avibactam injection product page.
Meblanios Aztreonam + Avibactam injection
Frequently Asked Questions
What are the common side effects of aztreonam + avibactam injection?
Reported adverse reactions include diarrhea, anemia and increases in liver enzymes such as ALT and AST. Other reported reactions include hypokalemia and pyrexia. The applicable product information should be consulted for the complete adverse-reaction profile.
What are the serious adverse reactions associated with aztreonam-avibactam?
Important safety concerns include hypersensitivity reactions, serious skin reactions, hepatic adverse reactions and Clostridioides difficile-associated diarrhea.
Is aztreonam-avibactam contraindicated in beta-lactam allergy?
A history of serious hypersensitivity to beta-lactam antibiotics requires careful assessment. The exact contraindications and warnings should be checked in the current product-specific prescribing information.
What monitoring may be needed during treatment?
Depending on the patient’s condition, monitoring may include renal function, liver-related laboratory tests, clinical signs of hypersensitivity, gastrointestinal symptoms and relevant hematologic parameters.
Can aztreonam-avibactam cause liver enzyme elevations?
Yes. Increases in ALT and AST have been reported. Liver-related laboratory monitoring may be appropriate when clinically indicated.
Are there important drug-interaction considerations?
Yes. The FDA multidisciplinary review evaluated CYP and transporter-related interaction potential, including OAT1/OAT3 considerations. A complete medication review should be performed using current product information.
Is safety information the same for every aztreonam-avibactam product?
Not necessarily. General information about the drug combination should be distinguished from product-specific prescribing information. Healthcare professionals should consult the applicable documentation for the product being administered.
Conclusion
The safety profile of aztreonam + avibactam injection should be evaluated through a combination of clinical evidence, regulatory information and patient-specific risk assessment.
Important considerations include hypersensitivity reactions, adverse gastrointestinal effects, hepatic laboratory abnormalities, hematologic changes, serious skin reactions, C. difficile-associated diarrhea, renal function and relevant drug-interaction considerations.
Monitoring should be individualized, with particular attention to renal function, liver-related laboratory tests and clinical signs of hypersensitivity or other serious adverse reactions.
Because regulatory recommendations and product information can change, healthcare professionals should use the current approved prescribing information for the specific aztreonam-avibactam product being administered.
For AIONIOS Pharma, this safety-focused resource complements existing content covering mechanism, dosing, renal dosing, susceptibility, pharmacokinetics, clinical evidence and injection preparation, while providing a distinct information layer around Aztreonam + Avibactam injection safety. The research specifically identified safety as a separate topical node rather than another variation of the existing Meblanios content. 3